179 related articles for article (PubMed ID: 11799336)
1. Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects.
Lane HY; Chang YC; Su MH; Chiu CC; Huang MC; Chang WH
J Clin Psychopharmacol; 2002 Feb; 22(1):4-10. PubMed ID: 11799336
[TBL] [Abstract][Full Text] [Related]
2. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients.
Chan WC; Lam LC; Choy CN; Leung VP; Li SW; Chiu HF
Int J Geriatr Psychiatry; 2001 Dec; 16(12):1156-62. PubMed ID: 11748775
[TBL] [Abstract][Full Text] [Related]
3. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F
J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121
[TBL] [Abstract][Full Text] [Related]
4. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.
Sultzer DL; Davis SM; Tariot PN; Dagerman KS; Lebowitz BD; Lyketsos CG; Rosenheck RA; Hsiao JK; Lieberman JA; Schneider LS;
Am J Psychiatry; 2008 Jul; 165(7):844-54. PubMed ID: 18519523
[TBL] [Abstract][Full Text] [Related]
5. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
6. Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.
Walther S; Moggi F; Horn H; Moskvitin K; Abderhalden C; Maier N; Strik W; Müller TJ
J Clin Psychopharmacol; 2014 Feb; 34(1):124-8. PubMed ID: 24346752
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances.
Suh GH; Son HG; Ju YS; Jcho KH; Yeon BK; Shin YM; Kee BS; Choi SK
Am J Geriatr Psychiatry; 2004; 12(5):509-16. PubMed ID: 15353389
[TBL] [Abstract][Full Text] [Related]
8. Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia.
Rainer MK; Masching AJ; Ertl MG; Kraxberger E; Haushofer M
J Clin Psychiatry; 2001 Nov; 62(11):894-900. PubMed ID: 11775050
[TBL] [Abstract][Full Text] [Related]
9. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group.
Katz IR; Jeste DV; Mintzer JE; Clyde C; Napolitano J; Brecher M
J Clin Psychiatry; 1999 Feb; 60(2):107-15. PubMed ID: 10084637
[TBL] [Abstract][Full Text] [Related]
10. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.
Deberdt WG; Dysken MW; Rappaport SA; Feldman PD; Young CA; Hay DP; Lehman DL; Dossenbach M; Degenhardt EK; Breier A
Am J Geriatr Psychiatry; 2005 Aug; 13(8):722-30. PubMed ID: 16085789
[TBL] [Abstract][Full Text] [Related]
11. Effect of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home.
Suh GH; Shah A
Int Psychogeriatr; 2005 Sep; 17(3):429-41. PubMed ID: 16252375
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of behavioral disorders in dementia with risperidone in psychogeriatric out-patients].
Kurz A; Delius-Stute H; Rettig K; Schwalen S
MMW Fortschr Med; 2003 Oct; 145 Suppl 3():89-95. PubMed ID: 15490773
[TBL] [Abstract][Full Text] [Related]
13. Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone.
Rabinowitz J; Katz IR; De Deyn PP; Brodaty H; Greenspan A; Davidson M
J Clin Psychiatry; 2004 Oct; 65(10):1329-34. PubMed ID: 15491235
[TBL] [Abstract][Full Text] [Related]
14. Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial.
Veser FH; Veser BD; McMullan JT; Zealberg J; Currier GW
J Psychiatr Pract; 2006 Mar; 12(2):103-8. PubMed ID: 16728906
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of perospirone on aggressive behavior associated with dementia.
Sato S; Mizukami K; Moro K; Tanaka Y; Asada T
Psychiatry Clin Neurosci; 2006 Feb; 60(1):106-9. PubMed ID: 16472367
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with risperidone in the treatment of behavioral and psychological symptoms of dementia.
Onor ML; Saina M; Trevisiol M; Cristante T; Aguglia E
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):205-9. PubMed ID: 17020789
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania.
Ouyang WC; Hsu MC; Yeh IN; Kuo CC
Int J Psychiatry Clin Pract; 2012 Sep; 16(3):178-88. PubMed ID: 22404731
[TBL] [Abstract][Full Text] [Related]
18. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T
Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871
[TBL] [Abstract][Full Text] [Related]
19. Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia.
Fang M; Chen H; Li LH; Wu R; Li Y; Liu L; Ye M; Huang J; Zhu S; Wang G; Zhang Q; Zheng H; Zhang L; Wang B; Zhou J; Zhao JP
Int Clin Psychopharmacol; 2012 Mar; 27(2):107-13. PubMed ID: 22233697
[TBL] [Abstract][Full Text] [Related]
20. Risperidone use in Korean patients with Alzheimer's disease: optimal dosage and effect on behavioural and psychological symptoms, cognitive function and activities of daily living.
Yoon JS; Kim JM; Lee H; Shin IS; Choi SK
Hum Psychopharmacol; 2003 Dec; 18(8):627-33. PubMed ID: 14696022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
